Pasithea Therapeutics Corp. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a classic biotech trade-off between clinical potential and financial sustainability. On one hand, Pasithea has successfully advanced PAS-004 into critical trials for advanced cancer and NF1, with a cash pile that provides a reasonable buffer for the next year. The move to a tablet formulation is a key technical catalyst that could differentiate the asset's efficacy profile. However, the acceleration of the cash burn and the loss of the ATM facility create a ticking clock for the company to produce meaningful clinical data. Ultimately, the investment case hinges on whether the clinical readouts for PAS-004 can arrive before the company is forced back into the capital markets for more funding. While the reclassification of warrants cleans up the balance sheet, it does not solve the fundamental need for non-dilutive revenue or strategic partnerships. Investors are left weighing the asymmetric upside of a successful MEK inhibitor against the high probability of further dilution in a challenging funding environment.